Paper42886331PubMed
Subtype-Specific Efficacy of Adrenoceptor Agonists in Inhibiting Lens-Induced Myopia in Chicks.
Uddin M and 6 others. Ophthalmic Physiol Opt, 2026.
Cite this record
ConductScience Library. Subtype-Specific Efficacy of Adrenoceptor Agonists in Inhibiting Lens-Induced Myopia in Chicks. Papers, record 42886331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42886331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Subtype-Specific Efficacy of Adrenoceptor Agonists in Inhibiting Lens-Induced Myopia in Chicks.
- Journal
- Ophthalmic Physiol Opt
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-16
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26875007 | Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. | Ophthalmology | 2016 | https://conductscience.org/library/papers/26875007 | PubMed |
| 2 | 8949710 | Risk of retinal detachment following cataract extraction: results from the International Cataract Surgery Outcomes Study. | Br J Ophthalmol | 1996 | https://conductscience.org/library/papers/8949710 | PubMed |
| 3 | 18812113 | Retinal detachment after phacoemulsification in high myopia: analysis of 2356 cases. | J Cataract Refract Surg | 2008 | https://conductscience.org/library/papers/18812113 | PubMed |
| 4 | 23499368 | Myopia-related fundus changes in Singapore adults with high myopia. | Am J Ophthalmol | 2013 | https://conductscience.org/library/papers/23499368 | PubMed |
| 5 | 21596297 | An evidence-based update on myopia and interventions to retard its progression. | J AAPOS | 2011 | https://conductscience.org/library/papers/21596297 | PubMed |
| 6 | 26271839 | Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. | Ophthalmology | 2016 | https://conductscience.org/library/papers/26271839 | PubMed |
| 7 | 30514630 | Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. | Ophthalmology | 2019 | https://conductscience.org/library/papers/30514630 | PubMed |
| 8 | 29715053 | A Review of Myopia Control with Atropine. | J Ocul Pharmacol Ther | 2018 | https://conductscience.org/library/papers/29715053 | PubMed |
| 9 | 21258611 | Pharmaceutical intervention for myopia control. | Expert Rev Ophthalmol | 2010 | https://conductscience.org/library/papers/21258611 | PubMed |
| 10 | 28494063 | Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. | JAMA Ophthalmol | 2017 | https://conductscience.org/library/papers/28494063 | PubMed |
| 11 | 40122578 | 3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial. | Br J Ophthalmol | 2025 | https://conductscience.org/library/papers/40122578 | PubMed |
| 12 | 38318144 | Myopia progression after cessation of atropine in children: a systematic review and meta-analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38318144 | PubMed |
| 13 | 21539592 | The M4 muscarinic antagonist MT-3 inhibits myopia in chick: evidence for site of action. | Ophthalmic Physiol Opt | 2011 | https://conductscience.org/library/papers/21539592 | PubMed |
| 14 | 29860464 | Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. | Invest Ophthalmol Vis Sci | 2018 | https://conductscience.org/library/papers/29860464 | PubMed |
| 15 | 8425826 | Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. | Invest Ophthalmol Vis Sci | 1993 | https://conductscience.org/library/papers/8425826 | PubMed |
| 16 | 21557730 | Adrenoceptor activity of muscarinic toxins identified from mamba venoms. | Br J Pharmacol | 2011 | https://conductscience.org/library/papers/21557730 | PubMed |
| 17 | 30699466 | Alpha2 -adrenoceptor agonists inhibit form-deprivation myopia in the chick. | Clin Exp Optom | 2019 | https://conductscience.org/library/papers/30699466 | PubMed |
| 18 | 38605375 | Brimonidine as a possible treatment for myopia. | BMC Ophthalmol | 2024 | https://conductscience.org/library/papers/38605375 | PubMed |
| 19 | 39309849 | The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye growth. | Heliyon | 2024 | https://conductscience.org/library/papers/39309849 | PubMed |
| 20 | 37955611 | Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion. | Invest Ophthalmol Vis Sci | 2023 | https://conductscience.org/library/papers/37955611 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42886331
GET https://conductscience.org/api/papers/v1/42886331/references?page=2